Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 212

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma

Open access
Cahill, Katherine N., Katz, Howard R., Cui, Jing, Lai, Juying, Kazani, Shamsah, Crosby-Thompson, Allison, Garofalo, Denise, Castro, Mario, Jarjour, Nizar, DiMango, Emily, Erzurum, Serpil, Trevor, Jennifer L., Shenoy, Kartik, Chinchilli, Vernon M., Wechsler, Michael E., Laidlaw, Tanya M., Boyce, Joshua A., Israel, Elliot·2017·New England Journal of Medicine

Abstract

BACKGROUNDMast cells are present in the airways of patients who have severe asthma despite glucocorticoid treatment; these cells are associated with disease characteristics including poor quality of life and inadequate asthma control.Stem cell factor and its receptor, KIT, are central to mast-cell homeostasis.We conducted a proof-ofprinciple trial to evaluate the effect of imatinib, a KIT inhibitor, on airway hyperresponsiveness, a physiological marker of severe asthma, as well as on airway mast-cell numbers and activation in patients with severe asthma. METHODSWe conducted a randomized, double-blind, placebo-controlled, 24-week trial of imatinib in patients with poorly controlled severe asthma who had airway hyperresponsiveness despite receiving maximal medical therapy.The primary end point was the change in airway hyperresponsiveness, measured as the concentration of methacholine required to decrease the forced expiratory volume in 1 second by 20% (PC 20 ).Patients also underwent bronchoscopy. RESULTSAmong the 62 patients who underwent randomization, imatinib treatment reduced airway hyperresponsiveness to a greater extent than did placebo.At 6 months, the methacholine PC 20 increased by a mean (±SD) of 1.73±0.60doubling doses in the imatinib group, as compared with 1.07±0.60doubling doses in the placebo group (P = 0.048).Imatinib also reduced levels of serum tryptase, a marker of mast-cell activation, to a greater extent than did placebo (decrease of 2.02±2.32 vs. 0.56±1.39ng per milliliter, P = 0.02).Airway mast-cell counts declined in both groups.Muscle cramps and hypophosphatemia were more common in the imatinib group than in the placebo group. CONCLUSIONSIn patients with severe asthma, imatinib decreased airway hyperresponsiveness, mastcell counts, and tryptase release.These results suggest that KIT-dependent processes and mast cells contribute to the pathobiologic basis of severe asthma.(Funded by the National Institutes of Health and others; ClinicalTrials.govnumber, NCT01097694.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1613125

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 212

Metadata

Authors
Cahill, K. N., Katz, H. R., Cui, J., Lai, J., Kazani, S., Crosby-Thompson, A., Garofalo, D., Castro, M., Jarjour, N., DiMango, E., Erzurum, S., Trevor, J. L., Shenoy, K., Chinchilli, V. M., Wechsler, M. E., Laidlaw, T. M., Boyce, J. A., & Israel, E.
Venue
New England Journal of Medicine
Published
2017-05-18
Volume
376
Issue
20
Pages
1911-1920
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2615078498
Cited by
212
References
2
FWCI
15.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. https://app.cochat.ai/papers/10.1056/nejmoa1613125
The paper
Cahill, K. N., Katz, H. R., Cui, J., Lai, J., Kazani, S., Crosby-Thompson, A., Garofalo, D., Castro, M., Jarjour, N., DiMango, E., Erzurum, S., Trevor, J. L., Shenoy, K., Chinchilli, V. M., Wechsler, M. E., Laidlaw, T. M., Boyce, J. A., & Israel, E. (2017). KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1613125

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.